12:00 AM
 | 
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Radium-223 regulatory update

Bayer submitted an MAA to EMA and an NDA to FDA for radium-223 dichloride to treat castration-resistant prostate cancer (CRPC) in patients with bone metastases. The MAA...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >